Recruiting
Phase 1
Phase 2

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Sponsor:

OncoC4, Inc.

Code:

NCT04140526

Conditions

Non Small Cell Lung Cancer

Advanced Solid Tumor

Metastatic Melanoma

Metastatic Head and Neck Carcinoma

Metastatic Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONC-392

Pembrolizumab

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information